Thyrocare Technologies Limited (THYROCARE) - Net Assets
Based on the latest financial reports, Thyrocare Technologies Limited (THYROCARE) has net assets worth Rs5.86 Billion INR (≈ $63.38 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs7.47 Billion ≈ $80.81 Million USD) and total liabilities (Rs1.61 Billion ≈ $17.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Thyrocare Technologies Limited growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs5.86 Billion |
| % of Total Assets | 78.43% |
| Annual Growth Rate | 15.49% |
| 5-Year Change | 11.29% |
| 10-Year Change | 44.06% |
| Growth Volatility | 20.7 |
Thyrocare Technologies Limited - Net Assets Trend (2011–2026)
This chart illustrates how Thyrocare Technologies Limited's net assets have evolved over time, based on quarterly financial data. Check strategic asset allocation of Thyrocare Technologies Limited to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Thyrocare Technologies Limited (2011–2026)
The table below shows the annual net assets of Thyrocare Technologies Limited from 2011 to 2026. For live market cap and overall valuation, see Thyrocare Technologies Limited (THYROCARE) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs5.86 Billion ≈ $63.38 Million |
+7.12% |
| 2025-03-31 | Rs5.47 Billion ≈ $59.16 Million |
+3.68% |
| 2024-03-31 | Rs5.28 Billion ≈ $57.06 Million |
-1.42% |
| 2023-03-31 | Rs5.35 Billion ≈ $57.88 Million |
+1.64% |
| 2022-03-31 | Rs5.27 Billion ≈ $56.95 Million |
+23.24% |
| 2021-03-31 | Rs4.27 Billion ≈ $46.21 Million |
+16.53% |
| 2020-03-31 | Rs3.67 Billion ≈ $39.65 Million |
-15.73% |
| 2019-03-31 | Rs4.35 Billion ≈ $47.06 Million |
-1.84% |
| 2018-03-31 | Rs4.43 Billion ≈ $47.94 Million |
+8.97% |
| 2017-03-31 | Rs4.07 Billion ≈ $43.99 Million |
+11.26% |
| 2016-03-31 | Rs3.66 Billion ≈ $39.54 Million |
+17.68% |
| 2015-03-31 | Rs3.11 Billion ≈ $33.60 Million |
+50.62% |
| 2014-03-31 | Rs2.06 Billion ≈ $22.31 Million |
+28.83% |
| 2013-03-31 | Rs1.60 Billion ≈ $17.31 Million |
+56.24% |
| 2012-03-31 | Rs1.02 Billion ≈ $11.08 Million |
+51.74% |
| 2011-03-31 | Rs675.33 Million ≈ $7.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Thyrocare Technologies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs1.59 Billion | 27.19% |
| Other Components | Rs4.26 Billion | 72.81% |
| Total Equity | Rs5.86 Billion | 100.00% |
Thyrocare Technologies Limited Competitors by Market Cap
The table below lists competitors of Thyrocare Technologies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Procter & Gamble Health Limited
NSE:PGHL
|
$1.07 Billion |
|
Inwido AB
ST:INWI
|
$1.07 Billion |
|
Puuilo Oyj
HE:PUUILO
|
$1.07 Billion |
|
Community Trust Bancorp Inc
NASDAQ:CTBI
|
$1.07 Billion |
|
SUPERLOOP LTD
F:9SL
|
$1.07 Billion |
|
SKAN Group AG
SW:SKAN
|
$1.07 Billion |
|
HJ ShipBuilding & Construction Co Ltd
KO:097230
|
$1.07 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
$1.07 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Thyrocare Technologies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 5,467,500,000 to 5,855,000,000, a change of 387,500,000 (7.1%).
- Net income of 1,630,400,000 contributed positively to equity growth.
- Dividend payments of 1,484,300,000 reduced retained earnings.
- Other comprehensive income decreased equity by 461,700,000.
- Other factors increased equity by 703,100,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.63 Billion | +27.85% |
| Dividends Paid | Rs1.48 Billion | -25.35% |
| Other Comprehensive Income | Rs-461.70 Million | -7.89% |
| Other Changes | Rs703.10 Million | +12.01% |
| Total Change | Rs- | 7.09% |
Book Value vs Market Value Analysis
This analysis compares Thyrocare Technologies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 49.49x to 16.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-03-31 | Rs12.57 | Rs622.10 | x |
| 2012-03-31 | Rs19.07 | Rs622.10 | x |
| 2013-03-31 | Rs36.66 | Rs622.10 | x |
| 2014-03-31 | Rs47.23 | Rs622.10 | x |
| 2015-03-31 | Rs55.50 | Rs622.10 | x |
| 2016-03-31 | Rs68.05 | Rs622.10 | x |
| 2017-03-31 | Rs75.79 | Rs622.10 | x |
| 2018-03-31 | Rs82.32 | Rs622.10 | x |
| 2019-03-31 | Rs81.32 | Rs622.10 | x |
| 2020-03-31 | Rs69.29 | Rs622.10 | x |
| 2021-03-31 | Rs80.69 | Rs622.10 | x |
| 2022-03-31 | Rs99.38 | Rs622.10 | x |
| 2023-03-31 | Rs100.79 | Rs622.10 | x |
| 2024-03-31 | Rs99.31 | Rs622.10 | x |
| 2025-03-31 | Rs102.05 | Rs622.10 | x |
| 2026-03-31 | Rs36.77 | Rs622.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Thyrocare Technologies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.85%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.67%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.28x
- Recent ROE (27.85%) is above the historical average (23.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 36.76% | 32.64% | 0.75x | 1.49x | Rs180.72 Million |
| 2012 | 34.10% | 32.78% | 0.78x | 1.34x | Rs246.95 Million |
| 2013 | 35.49% | 42.32% | 0.68x | 1.23x | Rs408.08 Million |
| 2014 | 22.38% | 30.72% | 0.61x | 1.19x | Rs255.30 Million |
| 2015 | 16.26% | 24.40% | 0.56x | 1.20x | Rs171.83 Million |
| 2016 | 14.17% | 21.50% | 0.59x | 1.12x | Rs152.39 Million |
| 2017 | 17.45% | 23.13% | 0.70x | 1.07x | Rs302.87 Million |
| 2018 | 21.04% | 26.18% | 0.74x | 1.08x | Rs489.46 Million |
| 2019 | 19.57% | 21.13% | 0.85x | 1.09x | Rs416.28 Million |
| 2020 | 24.11% | 20.41% | 0.92x | 1.28x | Rs517.34 Million |
| 2021 | 26.48% | 22.88% | 0.91x | 1.28x | Rs704.22 Million |
| 2022 | 33.45% | 29.91% | 0.97x | 1.15x | Rs1.23 Billion |
| 2023 | 12.07% | 12.24% | 0.83x | 1.18x | Rs110.60 Million |
| 2024 | 13.43% | 12.37% | 0.89x | 1.22x | Rs180.83 Million |
| 2025 | 16.74% | 13.31% | 0.99x | 1.27x | Rs368.35 Million |
| 2026 | 27.85% | 19.67% | 1.11x | 1.28x | Rs1.04 Billion |
Industry Comparison
This section compares Thyrocare Technologies Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,606,631,167
- Average return on equity (ROE) among peers: 16.69%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Thyrocare Technologies Limited (THYROCARE) | Rs5.86 Billion | 36.76% | 0.28x | $1.07 Billion |
| Krsnaa Diagnostics Limited (KRSNAA) | $8.10 Billion | 7.02% | 0.45x | $199.12 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $17.00 Billion | 14.05% | 0.40x | $3.53 Billion |
| Metropolis Healthcare Limited (METROPOLIS) | $5.25 Billion | 24.25% | 0.43x | $320.99 Million |
| Syngene International Limited (SYNGENE) | $28.21 Billion | 14.35% | 0.73x | $1.75 Billion |
| Vijaya Diagnostic Centre Limited (VIJAYA) | $2.74 Billion | 22.81% | 0.76x | $1.55 Billion |
| Vimta Labs Limited (VIMTALABS) | $2.34 Billion | 17.66% | 0.31x | $311.66 Million |
About Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical an… Read more